Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Study acronym: ENLIGHTEN-6
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Protocol Amendment History 2 changes
notable Trial sites reduced: 185 -> 173 locations 2026-07-19
notable Trial sites expanded: 180 -> 183 locations 2026-06-24
Trial Details
NCT Number NCT07392190
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 900 participants
Start Date 2026-02-10
Primary Completion 2028-06 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-17